Neurotechnology: what is the best device today?

Are brain chips really the whole neurotech story?

Brain chips are the loudest part of neurotechnology right now, but they are only one slice of the market.

When people ask “what is the best neurotech device today?”, they usually think about Neuralink, brain implants, cursor control, or someone moving a robotic arm with their thoughts. That is understandable. Those demos are spectacular. But neurotechnology is much wider than that.

A cochlear implant is neurotechnology. A deep brain stimulation system is neurotechnology. A responsive epilepsy implant is neurotechnology. A spinal cord stimulation system is neurotechnology. A focused ultrasound platform that targets brain circuits without opening the skull is also neurotechnology.

That changes the answer completely. If we only judge “most futuristic”, then Neuralink, Neuracle, Synchron, Precision Neuroscience, and Paradromics become the obvious shortlist. If we judge “best device today”, meaning proven benefit, regulatory maturity, patient impact, and technical defensibility, the answer moves toward cochlear implants, DBS, RNS, focused ultrasound, and spinal cord stimulation.

So everything starts with the definition.

The best neurotech device today is not automatically the most viral brain chip. It is the device that already turns nervous-system engineering into real daily function.

Is Neuralink actually the best neurotech device right now?

Neuralink is one of the most impressive frontier BCIs today, but it is not the best neurotechnology device overall.

The N1 implant is technically serious. It uses 1,024 electrodes across flexible threads, is implanted by a robot, records from motor cortex, and is designed to give people with paralysis digital autonomy. The newest CONVOY study also moves beyond computer cursor control and tests whether participants can control assistive devices such as a robotic arm.

That is a big deal. Neuralink is not just running a flashy demo loop anymore. It is actually trying to move from “a person can control a screen” to “a person can control useful external devices.” That is where BCI becomes more medically meaningful.

But compared with mature neurotech, Neuralink is still early. It has limited human data, no broad commercial approval, and no long-term proof that the interface stays stable for many years. Neuracle’s NEO already reached commercial approval in China. Synchron has a less invasive vascular route. Precision has an FDA-cleared temporary cortical interface. Paradromics is pushing hard toward speech, which may be the more valuable use case than cursor control.

So, Neuralink may be the most ambitious BCI brand today, but the best neurotech device today has to clear a higher bar than ambition.

If you want more recent data on this point, please see our latest neurotechnology market report.

If we judge by real patient impact, who wins?

Cochlear’s Nucleus platform is still the cleanest answer if we judge neurotechnology by proven human impact.

This may feel boring because cochlear implants are not new.

But that is exactly why they are so strong. They are real neural prostheses used at scale. They convert sound into electrical stimulation of the auditory nerve. They restore access to speech, education, work, and social life for people with severe hearing loss.

Cochlear’s Nucleus 8 processor stands out because it is small, light, connected, FDA-approved, and part of a mature implant ecosystem. Advanced Bionics is strong on remote programming and connected hearing care. MED-EL is strong on MRI compatibility and electrode-array flexibility. Those differences matter because cochlear implants are not just implants. They are long-term care systems with processors, fitting software, clinician workflows, remote support, MRI constraints, upgrades, and pediatric-to-adult pathways.

Cochlear wins today because the full system is more complete. Advanced Bionics has a real convenience angle with remote programming. MED-EL has a real surgical and MRI angle. But Cochlear combines scale, brand trust, processor maturity, connectivity, and clinical infrastructure better than anyone else.

At the end of the day, if neurotechnology means “a device that changes someone’s nervous-system function in the real world”, modern cochlear implants are still hard to beat.

Which brain stimulation device is ahead in hospitals?

Medtronic Percept RC is the strongest DBS device today because it pushes deep brain stimulation from fixed stimulation toward adaptive therapy.

Deep brain stimulation is already one of the most important neurotechnology categories. It is used for Parkinson’s disease, essential tremor, dystonia, and other movement disorders. The old DBS model was relatively simple: implant electrodes, program stimulation, adjust settings over time. The new model is more interesting because the device can also sense brain signals.

That is where Medtronic has the edge. Percept RC sits inside a platform that can use BrainSense technology, and Medtronic received FDA approval for adaptive DBS in Parkinson’s. The key point is not just rechargeability. Rechargeability is useful, but sensing and adaptation are strategically bigger. They move DBS closer to a device that listens before it stimulates.

Boston Scientific is a strong number two in this category. Its Vercise Genus system and Cartesia leads are very competitive because the 16-contact directional architecture gives clinicians more programming flexibility. Abbott’s Liberta RC is also serious because it has the smallest rechargeable DBS implant profile and can reduce charging to as few as ten times per year. That is a real patient-experience advantage.

Still, currently, Medtronic is ahead because the market is moving toward closed-loop stimulation, not just smaller batteries or more elegant leads. Boston Scientific looks very strong for programming precision. Abbott looks very strong for convenience. Medtronic looks strongest for where DBS is going next.

If you want more recent data on this point, please see our latest neurotechnology market report.

Who has the best epilepsy neurotech device?

NeuroPace RNS is the best epilepsy neurotechnology device because it is already a true closed-loop brain implant.

RNS is different from many stimulation devices because it records brain activity, detects abnormal patterns, and stimulates responsively. It is not constantly stimulating in a generic way. It is watching for patient-specific seizure activity and intervening when the pattern appears.

That makes it one of the clearest examples of what advanced neurotechnology should look like. It senses. It interprets. It acts. And it has long-term clinical evidence, including nine-year follow-up data showing seizure reductions that improve over time.

LivaNova’s VNS is easier to deploy in many patients because it stimulates the vagus nerve and avoids placing electrodes in the brain. That broader usability matters. DBS for epilepsy also has a role, especially when the seizure network is less focal. But RNS is more precise when a patient has one or two identifiable seizure foci and the clinician wants chronic intracranial data.

So the hierarchy is pretty clear. VNS is broader. DBS can be useful for network-level epilepsy. RNS is the sharper device when precision and brain recording matter most. Today, that makes NeuroPace one of the most underrated neurotech leaders.

Is there a top neurotech device that avoids brain surgery?

Insightec Exablate Neuro is the standout device when the patient wants brain-circuit treatment without an implant.

Exablate uses MRI-guided focused ultrasound to target specific brain regions involved in tremor and Parkinson’s symptoms. No implanted pulse generator. No lead tunneling. No battery replacement. No chronic hardware under the skin.

That tradeoff is powerful. DBS is still more adjustable and better suited for many patients who need long-term bilateral control. But Exablate has a completely different appeal: it can deliver a lesion-based treatment through focused acoustic energy, guided by MRI, without opening the skull.

Lately, the category has become more important because Exablate’s FDA indications have expanded over time, including essential tremor, tremor-dominant Parkinson’s, Parkinson’s-related dyskinesia and motor symptoms, and staged bilateral treatment in certain Parkinson’s patients. That makes it much more than a one-off tremor tool.

The comparison with DBS is not about which one is universally better. DBS is the stronger adjustable platform. Exablate is the cleaner no-implant option. For the right patient, especially someone who wants symptom relief without living with implanted hardware, Exablate is one of the most valuable neurotechnology devices on the market.

Is spinal cord stimulation quietly beating BCIs?

ONWARD’s ARC-EX may be less famous than Neuralink, but it is more practically important for many spinal cord injury patients today.

ARC-EX is not a brain implant. It is a non-invasive spinal cord stimulation system used with functional task practice to improve hand strength and sensation in people with cervical spinal cord injury. That sounds modest until we remember what hand function means in tetraplegia.

Better grip can mean eating with less help. Better sensation can mean safer object handling. Better hand control can mean using a phone, typing, grooming, or transferring with more independence. In spinal cord injury, those gains can matter more than a spectacular cursor demo.

The comparison with BCI is useful. Neuralink and Synchron try to bypass the damaged pathway by reading brain intent and controlling a digital or robotic output. ARC-EX tries to improve what remains inside the patient’s own body. That is a very different strategy. It is less cinematic, but it may scale faster because it is non-invasive, rehab-compatible, and now has regulatory clearance.

As seen above with other mature devices, the strongest neurotech is often the device that fits into care pathways fastest. ARC-EX is a good example: it does not need to win the “mind-control” narrative to be one of the most important neurotech products today.

If you want more recent data on this point, please see our latest neurotechnology market report.

Who is winning the invasive BCI race right now?

Neuracle’s NEO is currently ahead on approval, Neuralink is ahead on mindshare and electrode ambition, and Synchron is ahead on surgical simplicity.

That is the cleanest way to understand the BCI race. There is no single winner because the companies are solving different parts of the problem.

NEO, developed in China, became the first commercially approved invasive BCI medical device. That is a huge regulatory signal. Its design uses electrodes placed over the dura rather than deep penetrating threads, which probably makes it less invasive than Neuralink, but also likely limits signal richness.

Neuralink makes the opposite tradeoff. It goes for high-bandwidth intracortical recording with many electrodes and robotic implantation. The upside is richer signal capture. The downside is that long-term durability, surgical complexity, and regulatory proof are harder.

Synchron is playing a third game. Its Stentrode reaches the brain through blood vessels. That avoids open-brain surgery and makes the procedure feel closer to endovascular medicine than neurosurgical implantation. The signal may be lower bandwidth than direct cortical implants, but the route is easier to imagine scaling across hospitals.

Precision Neuroscience adds another angle. Its Layer 7 array sits on the cortical surface rather than penetrating deeply, and the company already received FDA clearance for temporary use. Paradromics is different again: it is betting on a high-data-rate implant for speech and communication.

So the BCI race is not one leaderboard. NEO has the approval lead. Neuralink has the high-bandwidth consumer imagination. Synchron has the least scary surgical story. Precision has the elegant cortical-surface approach. Paradromics has the most focused communication thesis.

Is speech actually the real BCI prize?

Speech is probably the most valuable BCI use case, even if cursor control gets more attention today.

Cursor control is useful. It gives people digital autonomy. It lets someone browse, message, work, and use software without moving their hands. Neuralink has made that feel very real.

But speech is a bigger human need. If someone with ALS, locked-in syndrome, or severe paralysis can communicate in text or synthetic voice at a useful speed, the device becomes more than a control interface. It becomes a social interface. It gives someone a way back into conversation.

That is why Paradromics matters. Its Connexus study is focused on restoring speech and computer control for people with severe motor impairment. The early study is small, but the target is sharp. A BCI that restores communication has a clearer medical reason to exist than a BCI that only makes computer control cooler.

Neuralink can still compete here, and it probably will. Precision and Synchron may also move toward communication. But today, Paradromics is one of the most interesting BCI companies because it is aiming at the highest-value interface: words, not clicks.

If you want more recent data on this point, please see our latest neurotechnology market report.

Are mental-health neurotech devices serious or still wellness gadgets?

Clinical TMS is serious neurotechnology; most consumer brain headsets are still much weaker.

BrainsWay and NeuroStar are the main examples here. They are not consumer wellness products. They are clinical transcranial magnetic stimulation platforms used for depression and other psychiatric indications. BrainsWay has expanded Deep TMS into adolescent depression, while NeuroStar has also built a large clinical footprint in TMS.

Flow FL-100 is the more interesting new angle because it brings prescription tDCS into the home for major depressive disorder. That matters because clinic-based TMS can be expensive, time-consuming, and hard to access. At-home neuromodulation could change the distribution model.

But we should not blur everything together. TMS has stronger clinical infrastructure and stimulation intensity. Flow has the access advantage. Consumer EEG headsets and broad “brain optimization” wearables sit far below both unless they show regulated clinical outcomes.

So yes, mental-health neurotechnology is serious when it is regulated, prescribed, and tied to measurable psychiatric outcomes. The weaker part of the market is the vague wellness layer that talks about focus, calm, or performance without the same clinical proof.

Do all neurotech categories deserve the same weight?

No. The categories that deserve the most weight are the ones that restore core function, already fit into medicine, and can prove outcomes with hard measures.

That gives cochlear implants, DBS, RNS, focused ultrasound, spinal cord stimulation, and clinical TMS a clear advantage today. They can be judged on hearing, tremor, seizure frequency, hand strength, sensation, depression scores, functional independence, or procedure burden.

BCI deserves a high strategic weight but a lower current-impact weight. The ceiling is enormous, especially for paralysis and speech. But most BCI devices still have small human datasets, difficult surgical questions, and unclear reimbursement pathways.

Consumer neurotech deserves the least weight in this ranking. Not because it is useless forever, but because most devices in that layer do not yet meet the standard we care about: regulated claim, measurable functional improvement, durable adoption, and a clear clinical buyer.

Everything considered together, the best neurotechnology categories today are less about “reading the mind” and more about restoring a specific function well enough that clinicians, patients, and payers can all understand the value.

So what is the ranking of best neurotech devices today?

Before ranking the devices, we need one simple rule: the winner is not the device with the most futuristic story, but the device with the strongest mix of patient impact, regulatory maturity, technical edge, and category importance today.

That is why the ranking below may look different from a hype ranking.

Neuralink is not number one because it is still investigational.

NEO ranks high inside BCI because it reached commercial approval, but it does not outrank mature therapeutic platforms.

ARC-EX ranks above several brain implants because it is already moving spinal cord stimulation into a real rehabilitation pathway.

Rank	Device	Category	Why it ranks here
1	Cochlear Nucleus 8 / modern cochlear implant stack	Auditory neuroprosthesis	This is the best neurotechnology device today because it restores a core human function at scale. Advanced Bionics is strong on remote programming and MED-EL is strong on MRI and electrode options, but Cochlear has the strongest overall mix of maturity, adoption, processor ecosystem, and clinical infrastructure.
2	Medtronic Percept RC / BrainSense adaptive DBS	Deep brain stimulation	Medtronic ranks second because DBS is already a major clinical category, and adaptive sensing pushes it toward closed-loop therapy. Boston Scientific is excellent on directional programming, and Abbott is excellent on rechargeable convenience, but Medtronic currently has the strongest future-facing DBS platform.
3	NeuroPace RNS	Closed-loop epilepsy implant	RNS is one of the most complete closed-loop neurotech devices: it records, detects, and stimulates. VNS is broader and easier to deploy, but RNS wins when focal precision and chronic brain data matter.
4	Insightec Exablate Neuro	MRI-guided focused ultrasound	Exablate ranks high because it treats movement-disorder symptoms without implanted hardware. DBS remains more adjustable, but Exablate owns the “no implant, no open skull” lane better than anyone.
5	ONWARD ARC-EX	Non-invasive spinal cord stimulation	ARC-EX deserves a high rank because hand strength and sensation are extremely meaningful outcomes in cervical spinal cord injury. It is less famous than BCI, but currently more ready for real rehabilitation use.
6	BrainsWay Deep TMS / NeuroStar	Clinical non-invasive brain stimulation	These platforms are serious because they already sit inside psychiatric care. BrainsWay has a strong indication-expansion story, while NeuroStar has a large clinical footprint. They rank below the top devices because the functional restoration is less direct than hearing, movement, or seizure control.
7	Neuracle NEO	Commercial invasive BCI	NEO ranks as the top BCI device today on regulatory reality. It reached commercial approval first, but its likely signal bandwidth and early clinical scope keep it below mature therapeutic neurotech.
8	Neuralink N1	High-bandwidth invasive BCI	Neuralink has the strongest BCI mindshare and one of the most ambitious technical designs. It ranks below NEO on approval and below mature medical devices on proof, but it remains one of the most important frontier platforms.
9	Synchron Stentrode	Endovascular BCI	Synchron’s strength is surgical scalability. A lower-bandwidth vascular implant may beat a higher-bandwidth cortical implant if it is much easier to place safely across hospitals. That tradeoff makes Stentrode strategically important.
10	Precision Neuroscience Layer 7	Cortical surface BCI	Precision has one of the cleanest design compromises: close to the brain, but not deeply penetrating it. Its FDA-cleared temporary cortical interface is a strong signal, though the permanent BCI product still needs more proof.
11	Paradromics Connexus	Speech-first high-data-rate BCI	Paradromics ranks lower today because it is still early, but the target is excellent. If speech restoration becomes the main BCI market, Connexus could move up fast.
12	Flow FL-100	At-home tDCS for depression	Flow is important because it brings prescription neuromodulation into the home. It ranks below clinical TMS because the category is newer and the evidence base is still being built, but the access story is strong.

What’s the best neurotech device today?

The best neurotechnology device today is the modern cochlear implant stack, with Cochlear’s Nucleus platform as the clearest leader.

That may sound less exciting than a brain chip, but it is the most honest answer. It restores a core human function, works at scale, has a mature clinical ecosystem, and keeps improving through processors, connectivity, fitting software, and remote care.

If we narrow the question to brain stimulation, Medtronic Percept RC is the strongest answer because adaptive DBS is where the category is moving.

If we narrow it to epilepsy, NeuroPace RNS is the standout because it is already a closed-loop brain implant with long-term evidence. If we narrow it to BCI, Neuracle NEO leads on approval, Neuralink leads on ambition, Synchron leads on surgical simplicity, and Paradromics may have the sharpest long-term use case if speech becomes the main prize.

Finally, the ranking tells us something bigger about neurotechnology today. The field is not being won by the devices with the most dramatic demos. It is being won by devices that solve one nervous-system problem clearly, safely, repeatedly, and in a way the medical system can actually absorb.

If you want more recent data on this point, please see our latest neurotechnology market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.